ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Conexeu Sciences (CNXU)
Conexeu Sciences stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$2.98▲ +1.36%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
44%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Conexeu Sciences in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Conexeu Sciences
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Conexeu Sciences a 44% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $2.38 and $3.43; in 9 out of 10, between $1.72 and $4.75. Estimated annual volatility is 102%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $87.4M
- 52-week high
- $18.79
- 52-week low
- $2.85
- Revenue (12 months)
- $0.0M
- Return on equity
- -332.9%
- Free cash flow (12 months)
- $-5.4M
- Beta
- 0.00
What this means
ATLAS does not publish a fair value for CNXU right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks CNXU has traded between $2.85 and $18.79. Today it is 84.1% below that high and 5% above its low.
Its beta is 0.00: it tends to move less than the market.
About the company
Conexeu Sciences Inc. is a biotechnology company focused on developing collagen-based regenerative biomaterial products for tissue restoration and repair.
Want to see everything about Conexeu Sciences?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Conexeu Sciences do?
Conexeu Sciences Inc. is a biotechnology company focused on developing collagen-based regenerative biomaterial products for tissue restoration and repair.
What is the chance CNXU goes up next month?
44%: somewhat worse than a coin flip. In half of the simulated outcomes, CNXU ends the month between $2.38 and $3.43.
How big is Conexeu Sciences and what is its P/E ratio?
Conexeu Sciences's market capitalization is $87.4M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is CNXU?
ATLAS estimates annual volatility at 102%. In a typical month, half of the outcomes end between $2.38 and $3.43.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer